N/A; N/A
N/a.; N/a.
Introduction and objectives: Immunotherapy has introduced advances in the treatment of non -small cell lung cancer. However, data from current clinical practice on potential responder groups, optimal duration of treatment and safety issues remain unclear. It is intended to produce a reflection on the population of patients with a favourable response to Pembrolizumab and how they have evolved clinically over tim...